Alan Ashworth

World-Renowned Cancer Researcher, Dr. Alan Ashworth, Joins Phoenix Molecular Designs Advisory Board

Retrieved on: 
Thursday, February 4, 2021
Branches of biology, Biology, Signal transduction, P110α, Ribosomal s6 kinase, Alan Ashworth, Cancer, Breast cancer, RSK, Phosphoinositide 3-kinase, Small molecule, Protein kinase inhibitor

SAN DIEGO and VANCOUVER,BC, Feb. 4, 2021 /PRNewswire/ - Phoenix Molecular Designs (PhoenixMD), an industry leader in the development of precise cancer therapeutics focusing on first-in-class RSK kinase inhibitors, today announced the appointment of Dr. Alan Ashworth PhD, FRS to their Advisory Board as a Scientific Advisor.

Key Points: 
  • SAN DIEGO and VANCOUVER,BC, Feb. 4, 2021 /PRNewswire/ - Phoenix Molecular Designs (PhoenixMD), an industry leader in the development of precise cancer therapeutics focusing on first-in-class RSK kinase inhibitors, today announced the appointment of Dr. Alan Ashworth PhD, FRS to their Advisory Board as a Scientific Advisor.
  • His team identified RSK2 using unbiased functional screens in search of novel drug targets for specific breast cancer subtypes.
  • This research launched Phoenix Molecular Designs in 2012, the only company to have developed a first-in-class small molecule against RSK.
  • Moreover, in the same article that highlighted RSK2 as a target for TNBC, Alan also identified PIK3CA as a target for luminal breast cancer.

Circle Pharma Appoints Alan Ashworth, PhD, FRS and Bruce Stillman, PhD, FRS to Its SAB

Retrieved on: 
Wednesday, October 21, 2020
Research, Venture capital, Genetics, Professional services, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Fellows of the Royal Society, Bruce William Stillman, Cold Spring Harbor Laboratory, Alan Ashworth, Stillman, CSHL, Biology, Organizations, Science and technology in the United States

Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, has appointed Prof. Alan Ashworth, PhD, FRS and Bruce Stillman, PhD, FRS to its Scientific Advisory Board.

Key Points: 
  • Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, has appointed Prof. Alan Ashworth, PhD, FRS and Bruce Stillman, PhD, FRS to its Scientific Advisory Board.
  • Dr. Stillman is the President and CEO of Cold Spring Harbor Laboratory (CSHL) in New York.
  • We are delighted that Alan and Bruce are joining our growing SAB.
  • Inhibition of Cyclin A has been shown to be synthetically lethal in cancers driven by mutations in the Rb pathway.